Patents by Inventor Qitao Xiao

Qitao Xiao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS
    Publication number: 20230002388
    Abstract: The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).
    Type: Application
    Filed: May 9, 2022
    Publication date: January 5, 2023
    Inventors: Haibing DENG, Jinbiao LIU, Counde OYANG, Ce WANG, Qitao XIAO, Guoliang XUN, Haiqiang ZENG
  • HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS
    Publication number: 20220289732
    Abstract: The present invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; (I) which are inhibitors of WDR5. The present invention also provides pharmaceutical compositions comprising such compounds, compositions comprising such compounds with an additional therapeutic agent and the therapeutic uses of such compounds.
    Type: Application
    Filed: August 7, 2020
    Publication date: September 15, 2022
    Inventors: Lichao FANG, Zhenting GAO, Xiangqing JIANG, Kevin Kun Chin LIU, Sing Yeung Frankie MAK, Counde OYANG, Ce WANG, Tao WANG, Jianping WU, Wu YINGMING, Qitao XIAO
  • Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents
    Patent number: 11420970
    Abstract: The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: August 23, 2022
    Assignee: NOVARTIS AG
    Inventors: Haibing Deng, Jinbiao Liu, Counde Oyang, Ce Wang, Qitao Xiao, Guoliang Xun, Haiqiang Zeng
  • Substituted 5-cyanoindole compounds and uses thereof
    Patent number: 10604502
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, and R5 are as defined herein.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: March 31, 2020
    Assignee: Novartis AG
    Inventors: Lei Du-Cuny, Qitao Xiao, Guoliang Xun, Qiangang Zheng
  • Cyano-substituted indoles as LSD1 inhibitors
    Patent number: 10590079
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, R5, and R6 are as defined herein.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: March 17, 2020
    Assignee: Novartis AG
    Inventors: Lei Du-Cuny, Feng He, Qitao Xiao, Guoliang Xun, Qiangang Zheng
  • IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY
    Publication number: 20190298715
    Abstract: Provided herein is the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.
    Type: Application
    Filed: September 29, 2017
    Publication date: October 3, 2019
    Inventors: Gregory Motz, Konstantinos John Mavrakias, Jinbiao Liu, Lei Liu, Qiangang Zheng, Guoliang Xun, Qitao Xiao
  • CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS
    Publication number: 20190092724
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, R5, and R6 are as defined herein.
    Type: Application
    Filed: February 28, 2017
    Publication date: March 28, 2019
    Inventors: Lei DU-CUNY, Feng HE, Qitao XIAO, Guoliang XUN, Qiangang ZHENG
  • SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF
    Publication number: 20190023684
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, and R5 are as defined herein.
    Type: Application
    Filed: June 19, 2018
    Publication date: January 24, 2019
    Inventors: Lei DU-CUNY, Qitao XIAO, Guoliang XUN, Qiangang ZHENG
  • IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY
    Publication number: 20190000880
    Abstract: Provided are the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.
    Type: Application
    Filed: December 30, 2016
    Publication date: January 3, 2019
    Inventors: Gregory Motz, Konstantinos John Mavrakias, Jinbiao Liu, Lei Liu, Qiangang Zheng, Guoliang Xun, Qitao Xiao